Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Current Deferred Revenue (2019)

Purple Biotech has reported Current Deferred Revenue over the past 1 years, most recently at $961000.0 for Q4 2019.

  • Quarterly Current Deferred Revenue changed N/A to $961000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $961000.0 through Dec 2019, changed N/A year-over-year, with the annual reading at $961000.0 for FY2019, N/A changed from the prior year.
  • Current Deferred Revenue was $961000.0 for Q4 2019 at Purple Biotech.
  • Over five years, Current Deferred Revenue peaked at $961000.0 in Q4 2019 and troughed at $961000.0 in Q4 2019.